{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:06:15Z","timestamp":1774627575729,"version":"3.50.1"},"reference-count":90,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.2353\/jmoldx.2006.060007","type":"journal-article","created":{"date-parts":[[2006,8,21]],"date-time":"2006-08-21T21:20:28Z","timestamp":1156195228000},"page":"397-411","source":"Crossref","is-referenced-by-count":67,"title":["JAK2 V617F in Myeloid Disorders: Molecular Diagnostic Techniques and Their Clinical Utility"],"prefix":"10.1016","volume":"8","author":[{"given":"David P.","family":"Steensma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.2353\/jmoldx.2006.060007_bib1","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.2353\/jmoldx.2006.060007_bib2","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.2353\/jmoldx.2006.060007_bib3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.2353\/jmoldx.2006.060007_bib4","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"The Lancet"},{"key":"10.2353\/jmoldx.2006.060007_bib5","doi-asserted-by":"crossref","first-page":"22788","DOI":"10.1074\/jbc.C500138200","article-title":"Identification of an acquired JAK2 mutation in Polycythemia vera","volume":"280","author":"Zhao","year":"2005","journal-title":"J Biol Chem"},{"key":"10.2353\/jmoldx.2006.060007_bib6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0268-960X(03)00024-9","article-title":"Receptor tyrosine kinases in normal and malignant haematopoiesis","volume":"17","author":"Reilly","year":"2003","journal-title":"Blood Rev"},{"key":"10.2353\/jmoldx.2006.060007_bib7","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.2353\/jmoldx.2006.060007_bib8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2174\/156652405774641106","article-title":"Kinases as drug discovery targets in hematologic malignancies","volume":"5","author":"Hannah","year":"2005","journal-title":"Curr Mol Med"},{"key":"10.2353\/jmoldx.2006.060007_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/(SICI)1098-1004(200001)15:1<7::AID-HUMU4>3.0.CO;2-N","article-title":"Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion","volume":"15","author":"den Dunnen","year":"2000","journal-title":"Hum Mutat"},{"key":"10.2353\/jmoldx.2006.060007_bib10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/10428190500301348","article-title":"JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?","volume":"47","author":"Nelson","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.2353\/jmoldx.2006.060007_bib11","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/sj.leu.2404064","article-title":"Chronic myeloproliferative disorders: a tyrosine kinase tale","volume":"20","author":"De Keersmaecker","year":"2005","journal-title":"Leukemia"},{"key":"10.2353\/jmoldx.2006.060007_bib12","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1182\/blood-2005-03-1287","article-title":"On the molecular origins of the chronic myeloproliferative disorders: it all makes sense","volume":"105","author":"Kaushansky","year":"2005","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2006.060007_bib13","doi-asserted-by":"crossref","first-page":"947","DOI":"10.4065\/80.7.947","article-title":"The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis","volume":"80","author":"Tefferi","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.2353\/jmoldx.2006.060007_bib14","series-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues","year":"2001"},{"key":"10.2353\/jmoldx.2006.060007_bib15","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.2353\/jmoldx.2006.060007_bib16","first-page":"87","article-title":"The diagnostic criteria of polycythaemia rubra vera","volume":"22","author":"Pearson","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.2353\/jmoldx.2006.060007_bib17","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/sj.leu.2404069","article-title":"Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis","volume":"20","author":"James","year":"2006","journal-title":"Leukemia"},{"key":"10.2353\/jmoldx.2006.060007_bib18","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.molmed.2005.10.003","article-title":"A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects","volume":"11","author":"James","year":"2005","journal-title":"Trends Mol Med"},{"key":"10.2353\/jmoldx.2006.060007_bib19","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","article-title":"The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u201catypical\u201d myeloproliferative disorders and myelodysplastic syndromes","volume":"106","author":"Steensma","year":"2005","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2006.060007_bib20","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2005-05-1898","article-title":"The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia","volume":"106","author":"Levine","year":"2005","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2006.060007_bib21","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood-2005-05-1800","article-title":"JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia","volume":"106","author":"Jelinek","year":"2005","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2006.060007_bib22","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/sj.onc.1209163","article-title":"The JAK2 V617F mutation in de novo acute myelogenous leukemias","volume":"25","author":"Lee","year":"2006","journal-title":"Oncogene"},{"key":"10.2353\/jmoldx.2006.060007_bib23","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1182\/blood-2005-09-3644","article-title":"Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7","volume":"107","author":"Frohling","year":"2006","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2006.060007_bib24","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2006.060007_bib25","first-page":"1696","article-title":"Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation","volume":"90","author":"McLornan","year":"2005","journal-title":"Haematologica"},{"key":"10.2353\/jmoldx.2006.060007_bib26","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/sj.leu.2403903","article-title":"JAK2 Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukemia","volume":"19","author":"Tono","year":"2005","journal-title":"Leukemia"},{"key":"10.2353\/jmoldx.2006.060007_bib27","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1038\/sj.leu.2403989","article-title":"The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients","volume":"19","author":"Ohyashiki","year":"2005","journal-title":"Leukemia"},{"key":"10.2353\/jmoldx.2006.060007_bib28","doi-asserted-by":"crossref","first-page":"112a","DOI":"10.1182\/blood.V106.11.369.369","article-title":"Presence of JAK2 mutations in MDS\/MPD-u WHO classified patients and not other forms of MDS suggests their derivation from classical myeloproliferative syndrome (Abstract 369)","volume":"106","author":"Szpurka","year":"2005","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2006.060007_bib29","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2141.2005.05747.x","article-title":"Ringed sideroblasts with thrombocytosis: an uncommon mixed myelodysplastic\/myeloproliferative disease of older adults","volume":"131","author":"Shaw","year":"2005","journal-title":"Br J Haematol"},{"key":"10.2353\/jmoldx.2006.060007_bib30","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/sj.leu.2404007","article-title":"Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"20","author":"McClure","year":"2006","journal-title":"Leukemia"},{"key":"10.2353\/jmoldx.2006.060007_bib31","doi-asserted-by":"crossref","first-page":"38a","DOI":"10.1182\/blood.V106.11.115.115","article-title":"Heterogeneous distribution of the JAK2 Val617Phe activating mutation in familial myeloproliferative disorders (Abstract 115)","volume":"106","author":"Bellanne-Chantelot","year":"2005","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2006.060007_bib32","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.leu.2404060","article-title":"Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia","volume":"20","author":"Kratz","year":"2006","journal-title":"Leukemia"},{"key":"10.2353\/jmoldx.2006.060007_bib33","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","article-title":"The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u201catypical\u201d myeloproliferative disorders and the myelodysplastic syndrome","volume":"106","author":"Steensma","year":"2005","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2006.060007_bib34","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2005-05-2087","article-title":"The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders","volume":"106","author":"Scott","year":"2005","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2006.060007_bib35","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2006.060007_bib36","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2141.2005.05776.x","article-title":"The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates","volume":"131","author":"Tefferi","year":"2005","journal-title":"Br J Haematol"},{"key":"10.2353\/jmoldx.2006.060007_bib37","doi-asserted-by":"crossref","first-page":"9152","DOI":"10.1158\/0008-5472.CAN-05-2017","article-title":"Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias","volume":"65","author":"Fitzgibbon","year":"2005","journal-title":"Cancer Res"},{"key":"10.2353\/jmoldx.2006.060007_bib38","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2005.05858.x","article-title":"The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia","volume":"132","author":"Cheung","year":"2006","journal-title":"Br J Haematol"},{"key":"10.2353\/jmoldx.2006.060007_bib39","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.2353\/jmoldx.2006.060007_bib40","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2005-08-3395","article-title":"The V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis","volume":"107","author":"Campbell","year":"2005","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2006.060007_bib41","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/asheducation-2005.1.409","article-title":"Platelets and thrombosis in myeloproliferative diseases","author":"Harrison","year":"2005","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"10.2353\/jmoldx.2006.060007_bib42","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/sj.leu.2403902","article-title":"Clinical implications of the JAK2 V617F mutation in essential thrombocythemia","volume":"19","author":"Antonioli","year":"2005","journal-title":"Leukemia"},{"key":"10.2353\/jmoldx.2006.060007_bib43","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","article-title":"JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance","volume":"131","author":"Wolanskyj","year":"2005","journal-title":"Br J Haematol"},{"key":"10.2353\/jmoldx.2006.060007_bib44","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1182\/blood-2005-04-1515","article-title":"The Jak2V617F mutation, PRV-1 overexpression and EEC formation define a similar cohort of MPD patients","volume":"106","author":"Goerttler","year":"2005","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2006.060007_bib45","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1126\/science.2443975","article-title":"A system for rapid DNA sequencing with fluorescent chain-terminating dideoxynucleotides","volume":"238","author":"Prober","year":"1987","journal-title":"Science"},{"key":"10.2353\/jmoldx.2006.060007_bib46","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1002\/1522-2683(200208)23:16<2720::AID-ELPS2720>3.0.CO;2-Z","article-title":"A general approach to the analysis of errors and failure modes in the base-calling function in automated fluorescent DNA sequencing","volume":"23","author":"Izmailov","year":"2002","journal-title":"Electrophoresis"},{"key":"10.2353\/jmoldx.2006.060007_bib47","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/1050-3862(92)90039-8","article-title":"Detection of single-base mutations in a mixed population of cells: a comparison of SSCP and direct sequencing","volume":"9","author":"Smith","year":"1992","journal-title":"Genet Anal Tech Appl"},{"key":"10.2353\/jmoldx.2006.060007_bib48","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/blood-2003-09-3360","article-title":"Acquired somatic ATRX mutations in myelodysplastic syndrome associated with alpha thalassemia (ATMDS) convey a more severe hematologic phenotype than germline ATRX mutations","volume":"103","author":"Steensma","year":"2004","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2006.060007_bib49","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2003-10-3579","article-title":"Enough already of the word \u201crobust\u201d!","volume":"103","author":"Steensma","year":"2004","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2006.060007_bib50","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1093\/nar\/17.7.2503","article-title":"Analysis of any point mutation in DNA: the amplification refractory mutation system (ARMS)","volume":"17","author":"Newton","year":"1989","journal-title":"Nucleic Acids Res"},{"key":"10.2353\/jmoldx.2006.060007_bib51","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0065-2423(05)40006-2","article-title":"Advances in real-time PCR: application to clinical laboratory diagnostics","volume":"40","author":"Kaltenboeck","year":"2005","journal-title":"Adv Clin Chem"},{"key":"10.2353\/jmoldx.2006.060007_bib52","series-title":"Molecular Diagnostics for the Clinical Laboratorian","first-page":"65","article-title":"PCR-based methods for mutation detection","author":"Frayling","year":"2006"},{"key":"10.2353\/jmoldx.2006.060007_bib53","doi-asserted-by":"crossref","first-page":"6937","DOI":"10.1021\/ja034716g","article-title":"Approaching real-time molecular diagnostics: single-pair fluorescence resonance energy transfer (spFRET) detection for the analysis of low abundant point mutations in K-ras oncogenes","volume":"125","author":"Wabuyele","year":"2003","journal-title":"J Am Chem Soc"},{"key":"10.2353\/jmoldx.2006.060007_bib54","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2141.2005.05682.x","article-title":"Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes","volume":"130","author":"Lasho","year":"2005","journal-title":"Br J Haematol"},{"key":"10.2353\/jmoldx.2006.060007_bib55","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood-2002-07-2341","article-title":"Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia","volume":"101","author":"Reeder","year":"2003","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.2353\/jmoldx.2006.060007_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/shem.2003.50026","article-title":"Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry","volume":"40","author":"Spivak","year":"2003","journal-title":"Semin Hematol"},{"key":"10.2353\/jmoldx.2006.060007_bib57","first-page":"1198","article-title":"Two new agents effective in Gleevec-resistant CML","volume":"3","year":"2004","journal-title":"Cancer Biol Ther"},{"key":"10.2353\/jmoldx.2006.060007_bib58","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Gilliland","year":"2002","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2006.060007_bib59","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/blood-2003-06-1824","article-title":"The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management","volume":"103","author":"Gotlib","year":"2004","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2006.060007_bib60","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"10.2353\/jmoldx.2006.060007_bib61","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2006.060007_bib62","doi-asserted-by":"crossref","first-page":"947","DOI":"10.4065\/80.7.947","article-title":"The JAK2 V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis","volume":"80","author":"Tefferi","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.2353\/jmoldx.2006.060007_bib63","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/sj.leu.2404069","article-title":"Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis","volume":"20","author":"James","year":"2006","journal-title":"Leukemia"},{"key":"10.2353\/jmoldx.2006.060007_bib64","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.patbio.2003.09.019","article-title":"Molecular markers for the diagnosis of Philadelphia chromosome negative myeloproliferative disorders","volume":"52","author":"Klippel","year":"2004","journal-title":"Pathol Biol (Paris)"},{"key":"10.2353\/jmoldx.2006.060007_bib65","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1182\/blood-2003-03-0744","article-title":"Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders","volume":"102","author":"Kralovics","year":"2003","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2006.060007_bib66","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4065\/74.2.159","article-title":"Diagnosing polycythemia vera: a paradigm shift","volume":"74","author":"Tefferi","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"10.2353\/jmoldx.2006.060007_bib67","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1182\/blood-2001-12-0349","article-title":"Polycythemia vera: myths, mechanisms, and management","volume":"100","author":"Spivak","year":"2002","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2006.060007_bib68","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/sj.thj.6200368","article-title":"Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia","volume":"5","author":"Michiels","year":"2004","journal-title":"Hematol J"},{"key":"10.2353\/jmoldx.2006.060007_bib69","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/cncr.21105","article-title":"Red cell mass and plasma volume measurements in polycythemia","volume":"104","author":"Sirhan","year":"2005","journal-title":"Cancer"},{"key":"10.2353\/jmoldx.2006.060007_bib70","first-page":"213","article-title":"The rise and fall of red cell mass measurement in polycythemia vera","volume":"4","author":"Tefferi","year":"2005","journal-title":"Curr Hematol Rep"},{"issue":"Suppl 10","key":"10.2353\/jmoldx.2006.060007_bib71","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/sonc.2002.33755","article-title":"Therapeutic options for essential thrombocythemia and polycythemia vera","volume":"29","author":"Solberg","year":"2002","journal-title":"Semin Oncol"},{"key":"10.2353\/jmoldx.2006.060007_bib72","first-page":"109","article-title":"Congenital polycythemias\/erythrocytoses","volume":"90","author":"Gordeuk","year":"2005","journal-title":"Haematologica"},{"key":"10.2353\/jmoldx.2006.060007_bib73","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1182\/blood.V90.5.2057","article-title":"Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias","volume":"90","author":"Kralovics","year":"1997","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2006.060007_bib74","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1365-2141.2002.03386.x","article-title":"Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia","volume":"117","author":"Messinezy","year":"2002","journal-title":"Br J Haematol"},{"key":"10.2353\/jmoldx.2006.060007_bib75","first-page":"1194","article-title":"Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis","volume":"89","author":"Mossuz","year":"2004","journal-title":"Haematologica"},{"key":"10.2353\/jmoldx.2006.060007_bib76","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/hep.1840050525","article-title":"Polycythemia and the Budd-Chiari syndrome: study of serum erythropoietin and bone marrow erythroid progenitors","volume":"5","author":"Levy","year":"1985","journal-title":"Hepatology"},{"key":"10.2353\/jmoldx.2006.060007_bib77","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood.V106.11.4964.4964","article-title":"Elevated erythropoietin levelsin polycythemia vera: diagnostic algorithms revisited (Abstract 4964)","volume":"106","author":"Thurmes","year":"2005","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2006.060007_bib78","first-page":"217","article-title":"Low serum erythropoietin: a strong diagnostic criterion of primary polycythaemia even at normal haemoglobin levels","volume":"17","author":"Messinezy","year":"1995","journal-title":"Clin Lab Haematol"},{"issue":"Suppl 2","key":"10.2353\/jmoldx.2006.060007_bib79","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0037-1963(01)90135-0","article-title":"Pathogenetic mechanisms of polycythemia vera and congenital polycythemic disorders","volume":"38","author":"Prchal","year":"2001","journal-title":"Semin Hematol"},{"key":"10.2353\/jmoldx.2006.060007_bib80","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0025-6196(12)61011-8","article-title":"Chromosome studies in 104 patients with polycythemia vera","volume":"66","author":"Diez-Martin","year":"1991","journal-title":"Mayo Clin Proc"},{"key":"10.2353\/jmoldx.2006.060007_bib81","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2141.2005.05543.x","article-title":"Essential thrombocythaemia: challenges and evidence-based management","volume":"130","author":"Harrison","year":"2005","journal-title":"Br J Haematol"},{"key":"10.2353\/jmoldx.2006.060007_bib82","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000064754","article-title":"Cytogenetic and molecular genetic aspects of essential thrombocythemia","volume":"108","author":"Steensma","year":"2002","journal-title":"Acta Haematol"},{"key":"10.2353\/jmoldx.2006.060007_bib83","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.4065\/80.9.1220","article-title":"bcr\/abl-negative, classic myeloproliferative disorders: diagnosis and treatment","volume":"80","author":"Tefferi","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.2353\/jmoldx.2006.060007_bib84","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood.V93.2.417","article-title":"A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications","volume":"93","author":"Harrison","year":"1999","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2006.060007_bib85","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1365-2141.2005.05719.x","article-title":"JAK2 V617F mutation is uncommon in chronic myelomonocytic leukaemia","volume":"130","author":"Johan","year":"2005","journal-title":"Br J Haematol"},{"key":"10.2353\/jmoldx.2006.060007_bib86","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/sj.onc.1209163","article-title":"The JAK2 V617F mutation in de novo acute myelogenous leukemias","volume":"25","author":"Lee","year":"2006","journal-title":"Oncogene"},{"key":"10.2353\/jmoldx.2006.060007_bib87","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/sj.leu.2404206","article-title":"JAK2 V617F is rare in de novo AML, but STAT3 activation is common and remains unexplained","volume":"20","author":"Steensma","year":"2006","journal-title":"Leukemia"},{"key":"10.2353\/jmoldx.2006.060007_bib88","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1056\/NEJMra020282","article-title":"The Budd-Chiari syndrome","volume":"350","author":"Menon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.2353\/jmoldx.2006.060007_bib89","doi-asserted-by":"crossref","first-page":"728a","DOI":"10.1182\/blood.V106.11.2588.2588","article-title":"Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome (Abstract 2588)","volume":"106","author":"Patel","year":"2005","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2006.060007_bib90","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1182\/blood-2003-10-3471","article-title":"Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin","volume":"103","author":"Ding","year":"2004","journal-title":"Blood"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157810603212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157810603212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T01:52:45Z","timestamp":1707184365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157810603212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":90,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["S1525157810603212"],"URL":"https:\/\/doi.org\/10.2353\/jmoldx.2006.060007","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}